Danielle N. Desautels

Winnipeg, MB R3E0T6, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

The Cardioprotective Effects of Empagliflozin with and Without ACE Inhibition in Chemotherapy-Induced Cardiotoxicity.

The Cardioprotective Effects of Empagliflozin with and Without ACE Inhibition in Chemotherapy-Induced Cardiotoxicity.

Journal: Biomedicines

Published: March 14, 2026

Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.

Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.

Journal: European heart journal open

Published: February 06, 2026

Can flaxseed "milk" prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)?

Can flaxseed "milk" prevent anthracycline mediated cardiotoxicity in women with breast cancer (CANFLAX-BC)?

Journal: Cardio-oncology (London, England)

Published: September 30, 2025

Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin-Induced Cardiotoxicity in Rats.

Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin-Induced Cardiotoxicity in Rats.

Journal: Journal of cellular and molecular medicine

Published: September 11, 2025

Improving Care for Older Adults with Cancer in Canada: A Call to Action.

Improving Care for Older Adults with Cancer in Canada: A Call to Action.

Journal: Current oncology (Toronto, Ont.)

Published: April 01, 2024

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

Journal: Cancer

Published: December 07, 2023

Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba.

Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba.

Journal: American journal of clinical oncology

Published: December 04, 2023

Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape.

Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape.

Journal: Current oncology (Toronto, Ont.)

Published: October 25, 2023

Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.

Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.

Journal: Computational and structural biotechnology journal

Published: November 08, 2022

Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.

Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.

Journal: JAMA oncology

Published: July 08, 2021

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.

Journal: Breast (Edinburgh, Scotland)

Published: June 11, 2021

Geographical variation and factors associated with gastric cancer in Manitoba.

Geographical variation and factors associated with gastric cancer in Manitoba.

Journal: PloS one

Published: January 06, 2021

Showing 1-12 of 30

Last Updated: 09/26/2026